APA (7th ed.) Citation

WS, C., TM, L., YS, C., YC, S., HC, H., TT, K., . . . CC, C. (2025). Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. Clinical and translational science, 18(3), e70177. https://doi.org/10.1111/cts.70177

Chicago Style (17th ed.) Citation

WS, Chen, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, and Chang CC. "Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas." Clinical and Translational Science 18, no. 3 (2025): e70177. https://doi.org/10.1111/cts.70177.

MLA (9th ed.) Citation

WS, Chen, et al. "Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas." Clinical and Translational Science, vol. 18, no. 3, 2025, p. e70177, https://doi.org/10.1111/cts.70177.